Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures

Published:2017-06 Issue: Volume:174 Page:1-21
ISSN:0163-7258
Container-title:Pharmacology & Therapeutics
language:en
Short-container-title:Pharmacology & Therapeutics

Author:

Lee Dae Ho

Publisher

Elsevier BV

Reference210 articles.

1. Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM);Ahn;Journal of Clinical Oncology,2016

2. 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial;Ahn;Journal of Thoracic Oncology,2016

3. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors;Akbay;Cancer Discovery,2013

4. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment;Alexandrova;Nature,2015

5. EGFR exon 20 insertion mutations in lung adenocarcinomas: Prevalence, molecular heterogeneity, and clinicopathologic characteristics;Arcila;Molecular Cancer Therapeutics,2013

Cited by 124 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating the polypharmacological potency of indenopyrazole against lung cancer oxidoreductase, chaperone, transferase, and hydrolase proteins;Medical Oncology;2025-05-09

2. Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Common Mutations: New Strategies;Cancers;2025-04-30

3. Metabolomic profiles altered by erlotinib encapsulated in poly(lactide-co-glycolide) nanoparticles in non-small cell lung cancer;Drug Development and Industrial Pharmacy;2025-03-27

4. Development of novel high-affinity nanobodies against EGFR for cancer therapy;2025-03-16

5. Adenocarcinoma Presenting as Pulmonary Ground Glass Opacities (GGOs): Every GGO Has Its Own Story;Annals of Surgical Oncology;2025-03-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.7亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2025 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3